Enovis (ENOV) Expected to Release Quarterly Earnings on Thursday

Enovis (NYSE:ENOV) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Enovis to post earnings of $0.7670 per share and revenue of $557.12 million for the quarter. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. During the same period in the previous year, the company earned $0.79 earnings per share. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. On average, analysts expect Enovis to post $3.15 EPS for the current fiscal year and $3.08 EPS for the next fiscal year.

Enovis Trading Up 1.1%

Shares of ENOV stock opened at $20.85 on Wednesday. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. Enovis has a 12-month low of $16.70 and a 12-month high of $32.41. The stock has a market capitalization of $1.20 billion, a P/E ratio of 6.16 and a beta of 1.31. The firm’s 50 day moving average is $19.82 and its 200 day moving average is $23.05.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ENOV shares. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a report on Saturday. Citigroup reaffirmed a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. UBS Group reiterated a “buy” rating and set a $44.00 price objective on shares of Enovis in a research report on Monday, October 5th. BMO Capital Markets set a $27.00 target price on Enovis in a report on Tuesday, September 1st. Finally, Needham & Company LLC dropped their target price on Enovis from $52.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.25.

Insider Activity

In other news, insider Oliver Engert bought 5,140 shares of Enovis stock in a transaction dated Thursday, September 3rd. The shares were purchased at an average cost of $19.46 per share, with a total value of $100,024.40. Following the completion of the acquisition, the insider owned 61,238 shares of the company’s stock, valued at $1,191,691.48. This trade represents a 9.16% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Damien Mcdonald bought 13,035 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was purchased at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the transaction, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This represents a 5.57% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 23,293 shares of company stock valued at $449,599 in the last three months. Insiders own 2.90% of the company’s stock.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.